HIGH-RISK PCI | LM

Monday, March 9, 2026

9:55 AM - 11:00 AM EST

Location: CRT Center Stage

Moderator(s)

Jeffrey W. Moses, MD, FSCAI

John and Myrna Daniels Professor of Cardiology
Columbia University Medical Center
New York, New York, United States

Disclosure(s): Abiomed (spouse): Consulting Fees (e.g., advisory boards) (Ongoing); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stock Options [in privately held companies] (Ongoing); Covanos: Stock Options [in privately held companies] (Ongoing); seimens: Consulting Fees (e.g., advisory boards) (Ongoing); Weightless Lead: Stock-privately held company (Ongoing)
David G. Rizik, MD, MSCAI, FACC

Health System Chief of Cardiovascular Service Line, Physician Executive Community Cardiovascular Research
Banner University Medicine, Scottsdale Arizona
Scottsdale, Arizona, United States

Disclosure(s): No financial relationships to disclose
Alfredo E. Rodriguez, MD,PhD

Director Cardiac Unit
Otamendi Hospital
CABA, Buenos Aires, Argentina

Disclosure information not submitted.

Disclosure(s):

Jeffrey W. Moses, MD, FSCAI: Abiomed (spouse): Consulting Fees (e.g., advisory boards) (Ongoing); Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, Xenter: Stock Options [in privately held companies] (Ongoing); Covanos: Stock Options [in privately held companies] (Ongoing); seimens: Consulting Fees (e.g., advisory boards) (Ongoing); Weightless Lead: Stock-privately held company (Ongoing)

David G. Rizik, MD, MSCAI, FACC: No financial relationships to disclose